Literature DB >> 465894

Backward walking and circling: behavioural responses induced by drug treatments which cause simultaneous release of catecholamines and 5-hydroxytryptamine.

G Curzon, J C Fernando, A J Lees.   

Abstract

1 The roles of catecholamine and 5-hydroxytryptamine (5-HT) release in mediating backward walking and circling were studied in rats. 2 These behaviours occurred in animals given 15 mg/kg intraperitoneally of (+)-amphetamine (which predominantly releases catecholamines) or either p-chloroamphetamine or fenfluramine (which predominantly release 5-HT). They also occurred when smaller doses of (+)-amphetamine (5 mg/kg) and either p-chloroamphetamine (2--5 mg/kg) or fenfluramine (5 mg/kg) were given together. 3 Characteristic dopamine-dependent behaviours (rearing, licking, gnawing) resulting from (+)-amphetamine injection were greatly reduced by p-chloroamphetamine or fenfluramine. 4 Characteristic 5-HT-dependent behaviours (wet dog shake, hind limb abduction) resulting from injection of either p-chloroamphetamine or fenfluramine were unaffected by (+)-amphetamine. 5 Fragmentary backward walking and circling resulting from levallorphan injection (50 mg/kg s.c.) were decreased by (+)-amphetamine at low dosage. 6 Results in general strengthen previous evidence that backward walking and circling are mediated by simultaneous dopamine and 5-HT release. 7 The possible relevance of the above findings to hallucinogenic activity, amphetamine psychosis, schizophrenia and abnormal movements due to L-DOPA treatment is discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 465894      PMCID: PMC2043578          DOI: 10.1111/j.1476-5381.1979.tb13696.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Action of some fluorinated amphetamine-like compounds on the synaptosomal uptake of neurotransmitters.

Authors:  J C Kouyoumdijian; M F Belin; J BARDAKDJIAN; P Gonnard
Journal:  J Neurochem       Date:  1976-09       Impact factor: 5.372

2.  Acute toxicity and gross behavioral effects of amphetamine, four methoxyamphetamines, and mescaline in rodents, dogs, and monkeys.

Authors:  W M Davis; J A Bedford; J L Buelke; M M Guinn; H T Hatoum; I W Waters; M C Wilson; M C Braude
Journal:  Toxicol Appl Pharmacol       Date:  1978-07       Impact factor: 4.219

Review 3.  The mode of action of indolamine and other hallucinogens.

Authors:  M R Boarder
Journal:  Essays Neurochem Neuropharmacol       Date:  1977

4.  Backward walking and circling: a behavioural response to concurrent catecholamine and 5-hydroxytryptamine release [proceedings].

Authors:  G Curzon; J C Fernando; A J Lees
Journal:  Br J Pharmacol       Date:  1979-05       Impact factor: 8.739

5.  Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines.

Authors:  S H Snyder
Journal:  Am J Psychiatry       Date:  1973-01       Impact factor: 18.112

6.  Serotonergic involvement in behavioural responses to amphetamine at high dosage.

Authors:  A J Lees; J C Fernando; G Curzon
Journal:  Neuropharmacology       Date:  1979-02       Impact factor: 5.250

7.  Serotonergic component of neuroleptic receptors.

Authors:  J E Leysen; C J Niemegeers; J P Tollenaere; P M Laduron
Journal:  Nature       Date:  1978-03-09       Impact factor: 49.962

8.  Comparison of tyrosine hydroxylase and dopamine-beta-hydroxylase inhibition with the effects of various 6-hydroxydopamine treatments on d-amphetamine induced motor activity.

Authors:  A S Hollister; G R Breese; B R Cooper
Journal:  Psychopharmacologia       Date:  1974-03-21

9.  L-Dopa-induced release of cerebral monoamines.

Authors:  K Y Ng; T N Chase; R W Colburn; I J Kopin
Journal:  Science       Date:  1970-10-02       Impact factor: 47.728

10.  Postural changes, tremor, and myoclonus in the rat immediately following injections of p-chloromaphetamine.

Authors:  J H Growdon
Journal:  Neurology       Date:  1977-11       Impact factor: 9.910

View more
  7 in total

Review 1.  Monitoring in vivo of transmitter metabolism by electrochemical methods.

Authors:  P H Hutson; G Curzon
Journal:  Biochem J       Date:  1983-04-01       Impact factor: 3.857

2.  Evaluation of sex differences in cannabinoid dependence.

Authors:  Julie A Marusich; Timothy W Lefever; Kateland R Antonazzo; Rebecca M Craft; Jenny L Wiley
Journal:  Drug Alcohol Depend       Date:  2014-02-12       Impact factor: 4.492

3.  5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine.

Authors:  M I Colado; T K Murray; A R Green
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

4.  Increased central 5-hydroxytryptamine receptor mechanisms in rats after chronic neuroleptic treatment.

Authors:  D Dawbarn; S K Long; C J Pycock
Journal:  Br J Pharmacol       Date:  1981-05       Impact factor: 8.739

5.  Previous experience disrupts d-amphetamine-induced stereotypic diving in rats.

Authors:  A D Petree; T L DeVietti
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Blockade of dopamine receptors explains the lack of 5-HT stereotypy on treatment with the putative 5-HT1A agonist LY165163.

Authors:  T P Donohoe; P H Hutson; G Curzon
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

7.  Experimental neurotoxicity of the anorectic fenfluramine. I. A fine structural model for cerebral lysosomal storage and neuroglial reaction.

Authors:  D K Dastur; B K Thakkar; P R Desai
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.